Timothy P.  Kelly net worth and biography

Timothy Kelly Biography and Net Worth

Tim is the chief technology officer of Caribou Biosciences and is responsible for the company’s technical operations strategy and execution, including seamless integration and alignment with Caribou’s corporate strategy. He brings over 25 years of experience in global clinical and commercial product development, manufacturing, and supply chain operations with both large and small biopharmaceutical and cell and gene therapy companies in the US and Europe. Tim joins Caribou from Oxford Biomedica Solutions, a spin-out of Homology Medicines, offering AAV product development and manufacturing services, where he was chief executive officer and board chair. Prior to Solutions, he was chief operating officer at Homology Medicines, Inc., where he led operations, process and platform development strategy, and product manufacturing strategy for gene therapy and gene editing technology. Earlier, he led technical operations at Sarepta, Shire, UCB, and Biogen, and was a fighter pilot in the US Air Force. Tim earned an MS/MBA from Troy State University and a BS, with emphasis in engineering mechanics, from the United States Air Force Academy.

What is Timothy P. Kelly's net worth?

The estimated net worth of Timothy P. Kelly is at least $127.36 thousand as of February 24th, 2026. Kelly owns 79,353 shares of Caribou Biosciences stock worth more than $127,362 as of August 6th. This net worth evaluation does not reflect any other assets that Kelly may own. Learn More about Timothy P. Kelly's net worth.

How do I contact Timothy P. Kelly?

The corporate mailing address for Kelly and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Timothy P. Kelly's contact information.

Has Timothy P. Kelly been buying or selling shares of Caribou Biosciences?

Timothy P. Kelly has not been actively trading shares of Caribou Biosciences during the last ninety days. Most recently, Timothy P. Kelly sold 3,147 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $1.96, for a transaction totalling $6,168.12. Following the completion of the sale, the chief technology officer now directly owns 79,353 shares of the company's stock, valued at $155,531.88. Learn More on Timothy P. Kelly's trading history.

Who are Caribou Biosciences' active insiders?

Caribou Biosciences' insider roster includes Tina Albertson (Insider), Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Rachel Haurwitz (CEO), Steven Kanner (Insider), Timothy Kelly (CTO), Ruhi Khan (Insider), Barbara McClung (Insider), and Sriram Ryali (CFO). Learn More on Caribou Biosciences' active insiders.

Are insiders buying or selling shares of Caribou Biosciences?

During the last year, insiders at the sold shares 4 times. They sold a total of 18,089 shares worth more than $35,454.44. The most recent insider tranaction occured on February, 24th when CTO Timothy P Kelly sold 3,147 shares worth more than $6,168.12. Insiders at Caribou Biosciences own 8.5% of the company. Learn More about insider trades at Caribou Biosciences.

Information on this page was last updated on 2/24/2026.

Timothy P. Kelly Insider Trading History at Caribou Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/24/2026Sell3,147$1.96$6,168.1279,353View SEC Filing Icon  
See Full Table

Timothy P. Kelly Buying and Selling Activity at Caribou Biosciences

This chart shows Timothy P Kelly's buying and selling at Caribou Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Caribou Biosciences Company Overview

Caribou Biosciences logo
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Read More

Today's Range

Now: $1.62
Low: $1.59
High: $1.68

50 Day Range

MA: $1.76
Low: $1.46
High: $2.43

2 Week Range

Now: $1.62
Low: $1.38
High: $3.54

Volume

444,772 shs

Average Volume

1,579,234 shs

Market Capitalization

$160.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38